Notice Number: NOT-DA-07-004
Release Date: November 7, 2006
National Institute on Drug Abuse (NIDA), (http://www.nida.nih.gov)
This Request for Information is a time-sensitive request to the positron emission tomography (PET) community directed toward determining some specific aspects related to better utilization of PET radiopharmaceutical imaging agents across centers. Based on the response from this inquiry, the NIH is considering initiatives to enhance the use of PET radiotracers beyond single disease applications to promote their use in multiple diseases as well as to increase collaborative efforts between sites. Initiatives developed will be aimed at complementing other, related efforts that presently exist as part of the NIH Roadmap. For example, a number of NIH Roadmap initiatives support the development of molecular probes to be used in exploring various diseases at molecular, cellular and in vivo levels, particularly the Molecular Libraries and Imaging initiative that has been established to identify lead compounds for tracer development, the Molecular Imaging & Contrast Agent Database (MICAD) that serves as an online resource for in vivo molecular imaging agents, and the Imaging Probe Development Center (IPDC) that has been established to produce known imaging probes where no viable commercial supplier exists and to develop novel imaging probes for research purposes. The initiatives envisioned to be created based on the responses to this RFI will be directed toward optimizing PET radiortacer development and use across diseases and between and among sites.
Despite significant progress over the past several years toward the better understanding and treatment of diseases, opportunities exist to critically advance our biomedical knowledge by optimizing technological developments in innovative and novel ways. With respect to positron emission tomography (PET), radiopharmaceutical imaging agents are typically developed with a specific system, utility, or disease entity in mind, but the targets are often relevant to multiple diseases. In an effort to facilitate development and utilization of clinically useful PET radiopharmaceutical imaging agents beyond a single utility or disease indication, the NIH is considering ways to provide incentives, to establish collaborations, to provide mechanisms to increase the availability of PET imaging probes across sites, and/or to facilitate the exchange of applicable clinical populations to test these probes further. In order to plan better, refine initiatives, and better serve the PET research community as it works toward better treatment and prevention of disease, the NIH requests information on the following points:
Please send email responses to Dr. Joseph Frascella no later than November 21, 2006 using “Resources for Optimizing Use of PET Radiotracers” in the subject line. Faxes may also be sent to the number below.
For additional information or questions, please contact:
Joseph Frascella, Ph.D.
Director, Division of Clinical Neuroscience and Behavioral Research
National Institute on Drug Abuse
National Institutes of Health
Rm. 3164, MSC 9593
6001 Executive Boulevard
Bethesda, Maryland 20892-9593
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Office of Extramural
National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
Department of Health
and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.